Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
244 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Epithelial Ovarian Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Epithelial Ovarian Cancer - Pipeline Review, H2 2014', provides an overview of the Epithelial Ovarian Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Epithelial Ovarian Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Epithelial Ovarian Cancer - Overview 9 Pipeline Products for Epithelial Ovarian Cancer - Comparative Analysis 10 Epithelial Ovarian Cancer - Therapeutics under Development by Companies 11 Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 15 Epithelial Ovarian Cancer - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Epithelial Ovarian Cancer - Products under Development by Companies 19 Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 21 Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 22 Johnson & Johnson 22 Boehringer Ingelheim GmbH 23 F. Hoffmann-La Roche Ltd. 24 Amgen Inc. 25 Oxford BioMedica plc 26 Millennium Pharmaceuticals, Inc. 27 ImmunoGen, Inc. 28 Bayer AG 29 Incyte Corporation 30 Active Biotech AB 31 Topotarget A/S 32 NeoStem, Inc. 33 Pharmacyclics, Inc. 34 Prima BioMed Ltd. 35 Synta Pharmaceuticals Corp. 36 Oasmia Pharmaceutical AB 37 Glycotope GmbH 38 BioNumerik Pharmaceuticals, Inc. 39 CerRx, Inc. 40 Immunotope, Inc. 41 Pharma Mar, S.A. 42 VentiRx Pharmaceuticals, Inc. 43 Clovis Oncology, Inc. 44 Recepta Biopharma S.A. 45 EGEN, Inc. 46 Sanofi Pasteur SA 47 AbbVie Inc. 48 Sotio a.s. 49 Epithelial Ovarian Cancer - Therapeutics Assessment 50 Assessment by Monotherapy Products 50 Assessment by Combination Products 51 Assessment by Target 52 Assessment by Mechanism of Action 56 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 65 trebananib - Drug Profile 65 paclitaxel - Drug Profile 69 cositecan - Drug Profile 71 bevacizumab - Drug Profile 73 trabectedin - Drug Profile 78 rucaparib phosphate - Drug Profile 81 sorafenib tosylate - Drug Profile 84 alisertib - Drug Profile 88 abiraterone acetate - Drug Profile 91 tasquinimod - Drug Profile 94 PankoMab-GEX - Drug Profile 96 elesclomol - Drug Profile 97 belinostat - Drug Profile 99 TroVax - Drug Profile 102 nintedanib - Drug Profile 105 CVac - Drug Profile 108 VTX-2337 - Drug Profile 111 RebmAb-100 - Drug Profile 113 EGEN-001 - Drug Profile 115 INCB-24360 - Drug Profile 117 DCVAC/OvCa - Drug Profile 119 Cancer Stem Cell Therapy - Drug Profile 121 fenretinide - Drug Profile 122 CDX-1401 - Drug Profile 124 ganetespib - Drug Profile 126 fosbretabulin tromethamine - Drug Profile 130 BNC-105P - Drug Profile 134 Cell Therapy Targeting Survivin and hTERT for Epithelial Ovarian Cancer - Drug Profile 136 Enadenotucirev - Drug Profile 137 OPB-111001 - Drug Profile 139 Cell Therapy Targeting NY-ESO-1 and LAGE-1 for Cancer - Drug Profile 140 Procure - Drug Profile 142 birinapant + conatumumab - Drug Profile 143 abexinostat hydrochloride - Drug Profile 145 nintedanib - Drug Profile 147 IMT-1012 - Drug Profile 150 vCP-2292 - Drug Profile 151 Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 153 Cell Therapy for Oncology - Drug Profile 154 IMGN-853 - Drug Profile 155 pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Drug Profile 156 anetumab ravtansine - Drug Profile 157 Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 159 Small Molecule for Oncology - Drug Profile 160 ABT-898 - Drug Profile 162 NERX-505X - Drug Profile 163 NERX-313E - Drug Profile 164 Epithelial Ovarian Cancer - Recent Pipeline Updates 165 Epithelial Ovarian Cancer - Dormant Projects 233 Epithelial Ovarian Cancer - Discontinued Products 234 Epithelial Ovarian Cancer - Product Development Milestones 235 Featured News & Press Releases 235 Appendix 240 Methodology 240 Coverage 240 Secondary Research 240 Primary Research 240 Expert Panel Validation 240 Contact Us 241 Disclaimer 241
List of Tables Number of Products under Development for Epithelial Ovarian Cancer, H2 2014 12 Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Development by Companies, H2 2014 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Late Stage Development, H2 2014 19 Comparative Analysis by Clinical Stage Development, H2 2014 20 Comparative Analysis by Early Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Investigation by Universities/Institutes, H2 2014 24 Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H2 2014 25 Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 26 Epithelial Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 27 Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H2 2014 28 Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica plc, H2 2014 29 Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 30 Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H2 2014 31 Epithelial Ovarian Cancer - Pipeline by Bayer AG, H2 2014 32 Epithelial Ovarian Cancer - Pipeline by Incyte Corporation, H2 2014 33 Epithelial Ovarian Cancer - Pipeline by Active Biotech AB, H2 2014 34 Epithelial Ovarian Cancer - Pipeline by Topotarget A/S, H2 2014 35 Epithelial Ovarian Cancer - Pipeline by NeoStem, Inc., H2 2014 36 Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 37 Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H2 2014 38 Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 39 Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 40 Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H2 2014 41 Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2014 42 Epithelial Ovarian Cancer - Pipeline by CerRx, Inc., H2 2014 43 Epithelial Ovarian Cancer - Pipeline by Immunotope, Inc., H2 2014 44 Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H2 2014 45 Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 46 Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 47 Epithelial Ovarian Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 48 Epithelial Ovarian Cancer - Pipeline by EGEN, Inc., H2 2014 49 Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H2 2014 50 Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H2 2014 51 Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H2 2014 52 Assessment by Monotherapy Products, H2 2014 53 Assessment by Combination Products, H2 2014 54 Number of Products by Stage and Target, H2 2014 57 Number of Products by Stage and Mechanism of Action, H2 2014 61 Number of Products by Stage and Route of Administration, H2 2014 64 Number of Products by Stage and Molecule Type, H2 2014 67 Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H2 2014 168 Epithelial Ovarian Cancer - Dormant Projects, H2 2014 236 Epithelial Ovarian Cancer - Discontinued Products, H2 2014 237
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
